Ken Griffin Ultragenyx Pharmaceutical Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,800 shares of RARE stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,800

Previous 23,400 48.72%

Holding current value

$1.56 Million

Previous $961,000 101.14%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $5.07 Million - $7.48 Million	-125,995 Reduced 72.43%	47,953 $2.66 Million
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $4.47 Million - $6.16 Million	-119,357 Reduced 40.69%	173,948 $7.15 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $4.01 Million - $5.01 Million	93,251 Added 46.61%	293,305 $13.7 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $6.3 Million - $9.77 Million	198,653 Added 14179.37%	200,054 $9.57 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $9.61 Million - $12.8 Million	-275,282 Reduced 99.49%	1,401 $49,000
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $10.5 Million - $14.7 Million	-281,133 Reduced 50.4%	276,683 $12.8 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $12.5 Million - $16.5 Million	337,840 Added 153.58%	557,816 $22.4 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $1.25 Million - $1.71 Million	36,970 Added 20.2%	219,976 $10.2 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $33.3 Million - $55.2 Million	-834,297 Reduced 82.01%	183,006 $7.58 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $13.6 Million - $25.4 Million	-297,729 Reduced 22.64%	1,017,303 $60.7 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $7.99 Million - $10.8 Million	-128,415 Reduced 8.9%	1,315,032 $95.5 Million
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $2.93 Million - $3.49 Million	-39,703 Reduced 2.68%	1,443,447 $121 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $29.1 Million - $38.2 Million	-373,329 Reduced 20.11%	1,483,150 $134 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $84.1 Million - $106 Million	911,966 Added 96.55%	1,856,479 $177 Million
Q1 2021 May 17, 2021	BUY	$106.9 - $167.73 $46.8 Million - $73.5 Million	438,003 Added 86.47%	944,513 $108 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $4.82 Million - $10.1 Million	57,123 Added 12.71%	506,510 $70.1 Million
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $15.2 Million - $18.7 Million	-207,833 Reduced 31.62%	449,387 $36.9 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $45.5 Million - $75.9 Million	-969,888 Reduced 59.61%	657,220 $51.4 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $4.34 Million - $8.08 Million	128,466 Added 8.57%	1,627,108 $72.3 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $38.2 Million - $48.6 Million	1,059,896 Added 241.57%	1,498,642 $64 Million
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $1.93 Million - $2.86 Million	-45,320 Reduced 9.36%	438,746 $18.8 Million
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $26.9 Million - $36.4 Million	-490,006 Reduced 50.3%	484,066 $30.7 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $38.4 Million - $66.8 Million	963,599 Added 9200.79%	974,072 $0
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $7.09 Million - $14.1 Million	-182,348 Reduced 94.57%	10,473 $455,000
Q3 2018 Nov 13, 2018	SELL	$71.81 - $90.15 $19.7 Million - $24.8 Million	-274,751 Reduced 58.76%	192,821 $0
Q2 2018 Aug 10, 2018	SELL	$48.54 - $85.31 $825,519 - $1.45 Million	-17,007 Reduced 3.51%	467,572 $0
Q1 2018 May 11, 2018	BUY	$44.33 - $58.52 $8.43 Million - $11.1 Million	190,219 Added 64.62%	484,579 $24.7 Million
Q4 2017 Feb 09, 2018	BUY	$43.54 - $57.32 $11.7 Million - $15.4 Million	269,271 Added 1073.26%	294,360 $13.7 Million
Q3 2017 Nov 09, 2017	BUY	$49.79 - $66.32 $1.25 Million - $1.66 Million	25,089	25,089 $1.34 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account